- In patients with early-stage clear cell ovarian cancer, adjuvant chemotherapy does not improve OS in the overall population, but extends OS in those with stage IC.
Why this matters
- International guidelines recommended adjuvant chemotherapy regardless of stage and histological classification.
- Meta-analysis shows stage IA/B patients do not derive a survival benefit from adjuvant chemotherapy.
- A meta-analysis of 7 studies including 5073 patients with stage I clear cell ovarian cancer.
- Funding: None.
- Median follow-up ranged from 30 months to 6.21 years.
- 72.5% of patients received adjuvant chemotherapy.
- Overall, 5-year disease-free survival (DFS) and OS were 83.7% and 86.9%, respectively.
- Overall, adjuvant chemotherapy vs observation yielded no statistical difference in:
- 5-year DFS: 83.3% vs 84.4% (risk difference, 0.01; P=.86).
- 5-year OS: 88.4% vs 84.7% (risk difference, 0.85; P=.53).
- In patients with stage IC disease, significant improvement in OS was seen with adjuvant chemotherapy vs observation (OR, 0.70; P=.01).
- All included studies were retrospective.
- Heterogeneity across studies.